11 results on '"Barone, Marialucia"'
Search Results
2. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
- Author
-
Morabito, Fortunato, primary, Zamagni, Elena, additional, Conticello, Concetta, additional, Pavone, Vincenzo, additional, Palmieri, Salvatore, additional, Bringhen, Sara, additional, Galli, Monica, additional, Mangiacavalli, Silvia, additional, Derudas, Daniele, additional, Rossi, Elena, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Tacchetti, Paola, additional, Mele, Giuseppe, additional, Vincelli, Iolanda Donatella, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Mendicino, Francesco, additional, Botta, Cirino, additional, Mele, Anna, additional, Pantani, Lucia, additional, Rocchi, Serena, additional, Garibaldi, Bruno, additional, Cascavilla, Nicola, additional, Ballanti, Stelvio, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Falcone, Antonetta Pia, additional, Cangialosi, Clotilde, additional, Reddiconto, Giovanni, additional, Farina, Giuliana, additional, Barone, Marialucia, additional, Rizzello, Ilaria, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Curci, Paola, additional, Gamberi, Barbara, additional, Musto, Pellegrino, additional, De Stefano, Valerio, additional, Musso, Maurizio, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Di Raimondo, Francesco, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, and Gentile, Massimo, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
- Author
-
Morabito, Fortunato, primary, Zamagni, Elena, additional, Conticello, Concetta, additional, Pavone, Vincenzo, additional, Palmieri, Salvatore, additional, Bringhen, Sara, additional, Galli, Monica, additional, Mangiacavalli, Silvia, additional, Derudas, Daniele, additional, Rossi, Elena, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Tacchetti, Paola, additional, Mele, Giuseppe, additional, Donatella Vincelli, Iolanda, additional, Antonia Martino, Enrica, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Bruzzese, Antonella, additional, Mele, Anna, additional, Pantani, Lucia, additional, Rocchi, Serena, additional, Garibaldi, Bruno, additional, Cascavilla, Nicola, additional, Ballanti, Stelvio, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Pia Falcone, Antonetta, additional, Cangialosi, Clotilde, additional, Reddiconto, Giovanni, additional, Farina, Giuliana, additional, Barone, Marialucia, additional, Rizzello, Ilaria, additional, Musto, Pellegrino, additional, De Stefano, Valerio, additional, Musso, Maurizio, additional, Teresa Petrucci, Maria, additional, Offidani, Massimo, additional, Neri, Antonino, additional, Di Renzo, Nicola, additional, Di Raimondo, Francesco, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, and Gentile, Massimo, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
- Author
-
Martino, Enrica Antonia, Conticello, Concetta, Zamagni, Elena, Pavone, Vincenzo, Palmieri, Salvatore, Musso, Maurizio, Tacchetti, Paola, Mele, Anna, Catalano, Lucio, Vigna, Ernesto, Bruzzese, Antonella, Mendicino, Francesco, Botta, Cirino, Vincelli, Iolanda Donatella, Farina, Giuliana, Barone, Marialucia, Cangialosi, Clotilde, Mancuso, Katia, Rizziello, Ilaria, and Rocchi, Serena
- Subjects
MULTIPLE myeloma ,CLINICAL trials ,SALVAGE therapy ,LENALIDOMIDE ,PROGRESSION-free survival ,ARRHYTHMIA ,HEART failure - Abstract
In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of investigation by many groups to confirm ASPIRE results in the setting of RRMM treated in real‐life who don't meet trial restrictive inclusion criteria. Therefore, we report a retrospective multicenter analysis of 600 RRMM patients treated with KRd between December 2015 and December 2018. The median age was 64 years (range 33–85), and the median number of previous therapies was two (range 1–11). After a median of 11 KRd cycles, the overall response rate was 79.9%. The median progression‐free survival (PFS) was 22 months, and the 2‐year probability of PFS was 47.6%. Creatinine clearance<30 ml/min, >1 line of previous therapy, and high‐risk FISH were all associated with a poor prognosis in multivariate analysis. The median overall survival (OS) was 34.8 months; the 2‐year probability of OS was 63.5%. At multivariate analysis, creatinine clearance<30 ml/min, >1 line of previous therapy, and high‐risk FISH were significantly associated with poor prognosis. After a median follow‐up of 16 months (range 1–50), 259 withdrew from therapy. The main discontinuation reason was progressive disease (81.8%). Seventy‐four patients (12.3%) discontinued therapy for toxicity. The most frequent side effects were hematological (anemia 49.3%, neutropenia 42.7%, thrombocytopenia 42.5%) and cardiovascular (hypertension 14.5%, heart failure 2.5%, arrhythmias 3.6%). Our study confirms the safety and efficacy of KRd in the real‐life setting of RRMM patients and encourages its use in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Bortezomib and Plasma Cell Leukemia.
- Author
-
Musto, Pellegrino, primary, Barone, Marialucia, additional, Guariglia, Roberto, additional, Pietrantuono, Giuseppe, additional, Gay, Francesca, additional, Rossini, Fausto, additional, Guglielmelli, Tommasina, additional, Pitini, Vincenzo, additional, Ferrara, Felicetto, additional, Galli, Monica, additional, Falcone, Antonietta, additional, Pozzi, Samantha, additional, D’auria, Fiorella, additional, Sacchi, Stefano, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional
- Published
- 2006
- Full Text
- View/download PDF
6. Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.
- Author
-
Musto, Pellegrino, primary, Luminari, Stefano, additional, De Renzo, Amalia, additional, Persico, Marcello, additional, Iannitto, Emilio, additional, Dell’Olio, Matteo, additional, Vallisa, Daniele, additional, Pozzi, Samantha, additional, Ferreri, Andres, additional, Angrilli, Francesco, additional, Mazza, Patrizio, additional, Quarta, Giovanni, additional, Guariglia, Roberto, additional, Barone, Marialucia, additional, Pietrantuono, Giuseppe, additional, D’Auria, Fiorella, additional, Perna, Fabiana, additional, Lamura, Vincenzo, additional, Pulsoni, Alessandro, additional, Marcucci, Fabrizio, additional, Mele, Alfonso, additional, Sacchi, Stefano, additional, and Rotoli, Bruno, additional
- Published
- 2006
- Full Text
- View/download PDF
7. Role of Parenteral Nutrition in Cancer Patients Undergoing High-Dose Chemotherapy Followed by Autologous Peripheral Blood Progenitor Cell Transplantation
- Author
-
Tartarone, Alfredo, primary, Wunder, Jenna, additional, Romano, Gianpiero, additional, Ardito, Raffaele, additional, lodice, Giovanni, additional, Mazzuoli, Silvia, additional, Barone, Marialucia, additional, Matera, Rosella, additional, and Di Renzo, Nicola, additional
- Published
- 2005
- Full Text
- View/download PDF
8. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
- Author
-
Enrica Antonia Martino, Concetta Conticello, Elena Zamagni, Vincenzo Pavone, Salvatore Palmieri, Maurizio Musso, Paola Tacchetti, Anna Mele, Lucio Catalano, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Iolanda Donatella Vincelli, Giuliana Farina, Marialucia Barone, Clotilde Cangialosi, Katia Mancuso, Ilaria Rizziello, Serena Rocchi, Antonietta Pia Falcone, Giuseppe Mele, Giovanni Reddiconto, Bruno Garibaldi, Enrico Iaccino, Giovanni Tripepi, Barbara Gamberi, Francesco Di Raimondo, Pellegrino Musto, Antonino Neri, Michele Cavo, Fortunato Morabito, Massimo Gentile, Martino, Enrica Antonia, Conticello, Concetta, Zamagni, Elena, Pavone, Vincenzo, Palmieri, Salvatore, Musso, Maurizio, Tacchetti, Paola, Mele, Anna, Catalano, Lucio, Vigna, Ernesto, Bruzzese, Antonella, Mendicino, Francesco, Botta, Cirino, Vincelli, Iolanda Donatella, Farina, Giuliana, Barone, Marialucia, Cangialosi, Clotilde, Mancuso, Katia, Rizziello, Ilaria, Rocchi, Serena, Falcone, Antonietta Pia, Mele, Giuseppe, Reddiconto, Giovanni, Garibaldi, Bruno, Iaccino, Enrico, Tripepi, Giovanni, Gamberi, Barbara, Di Raimondo, Francesco, Musto, Pellegrino, Neri, Antonino, Cavo, Michele, Morabito, Fortunato, and Gentile, Massimo
- Subjects
Salvage Therapy ,Cancer Research ,Oncology ,Humans ,Hematology ,General Medicine ,KRd regimen, multiple myeloma, salvage therapy ,Multiple Myeloma ,Lenalidomide ,Dexamethasone ,Retrospective Studies - Abstract
In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of investigation by many groups to confirm ASPIRE results in the setting of RRMM treated in real-life who don't meet trial restrictive inclusion criteria. Therefore, we report a retrospective multicenter analysis of 600 RRMM patients treated with KRd between December 2015 and December 2018. The median age was 64 years (range 33-85), and the median number of previous therapies was two (range 1-11). After a median of 11 KRd cycles, the overall response rate was 79.9%. The median progression-free survival (PFS) was 22 months, and the 2-year probability of PFS was 47.6%. Creatinine clearance30 ml/min,1 line of previous therapy, and high-risk FISH were all associated with a poor prognosis in multivariate analysis. The median overall survival (OS) was 34.8 months; the 2-year probability of OS was 63.5%. At multivariate analysis, creatinine clearance30 ml/min,1 line of previous therapy, and high-risk FISH were significantly associated with poor prognosis. After a median follow-up of 16 months (range 1-50), 259 withdrew from therapy. The main discontinuation reason was progressive disease (81.8%). Seventy-four patients (12.3%) discontinued therapy for toxicity. The most frequent side effects were hematological (anemia 49.3%, neutropenia 42.7%, thrombocytopenia 42.5%) and cardiovascular (hypertension 14.5%, heart failure 2.5%, arrhythmias 3.6%). Our study confirms the safety and efficacy of KRd in the real-life setting of RRMM patients and encourages its use in clinical practice.
- Published
- 2022
9. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
- Author
-
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Antonino Neri, Massimo Gentile, Morabito, Fortunato, Zamagni, Elena, Conticello, Concetta, Pavone, Vincenzo, Palmieri, Salvatore, Bringhen, Sara, Galli, Monica, Mangiacavalli, Silvia, Derudas, Daniele, Rossi, Elena, Ria, Roberto, Catalano, Lucio, Tacchetti, Paola, Mele, Giuseppe, Vincelli, Iolanda Donatella, Martino, Enrica Antonia, Vigna, Ernesto, Bruzzese, Antonella, Mendicino, Francesco, Botta, Cirino, Mele, Anna, Pantani, Lucia, Rocchi, Serena, Garibaldi, Bruno, Cascavilla, Nicola, Ballanti, Stelvio, Tripepi, Giovanni, Frigeri, Ferdinando, Falcone, Antonetta Pia, Cangialosi, Clotilde, Reddiconto, Giovanni, Farina, Giuliana, Barone, Marialucia, Rizzello, Ilaria, Iaccino, Enrico, Mimmi, Selena, Curci, Paola, Gamberi, Barbara, Musto, Pellegrino, De Stefano, Valerio, Musso, Maurizio, Petrucci, Maria Teresa, Offidani, Massimo, Di Raimondo, Francesco, Boccadoro, Mario, Cavo, Michele, Neri, Antonino, and Gentile, Massimo
- Subjects
multiple myeloma ,Cancer Research ,carfilzomib ,Oncology ,lenalidomide ,survival ,elotuzumab ,prognosi ,prognostic score ,relapsed/refractory - Abstract
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no difference between the two strategies. The multivariate model identified a significant progression/death risk increase for ISS III (HR = 1.37; P = 0.002), >3 previous lines of therapies (HR = 1.67; P < 0.0001), older age (HR = 1.64; P < 0.0001), and prior lenalidomide exposure (HR = 1.35; P = 0.003). Three risk SRSKRd/EloRd categories were generated: low-risk (134 cases, 16.5%), intermediate-risk (467 cases, 57.3%), and high-risk categories (213 cases, 26.2%). The 1- and 2-year OS probability rates were 92.3% and 83.8% for the low-risk (HR = 1, reference category), 81.1% and 60.6% (HR = 2.73; P < 0.0001) for the intermediate-risk, and 65.5% and 42.5% (HR = 4.91; P < 0.0001) for the high-risk groups, respectively. Notably, unlike the low-risk group, which did not cross the median timeline, the OS median values were 36.6 and 18.6 months for the intermediate- and high-risk cases, respectively. Similarly, three PRSKRd/EloRd risk categories were engendered. Based on such grouping, 338 (41.5%) cases were allocated in the low-, 248 (30.5%) in the intermediate-, and 228 (28.0%) in the high-risk groups. The 1- and 2-year PFS probability rates were 71.4% and 54.5% for the low-risk (HR = 1, reference category), 68.9% and 43.7% (HR = 1.95; P < 0.0001) for the intermediate-risk, and 48.0% and 27.1% (HR = 3.73; P < 0.0001) for the high-risk groups, respectively. The PFS median values were 29.0, 21.0, and 11.7 months for the low-, intermediate-, and high-risk cases. This analysis showed 2.7- and 4.9-fold increased risk of death for the intermediate- and high-risk cases treated with KRd/EloRd as salvage therapy. The combined progression/death risks of the two categories were increased 1.3- and 2.2-fold compared to the low-risk group. In conclusion, SRSKRd/EloRd and PRSKRd/EloRd may represent accessible and globally applicable models in daily clinical practice and ultimately represent a prognostic tool for RRMM patients who received KRd or EloRd.
- Published
- 2022
10. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
- Author
-
Valerio De Stefano, Lucio Catalano, Lucia Pantani, Pellegrino Musto, Elena Rossi, Enrica Antonia Martino, Antonetta Pia Falcone, Ernesto Vigna, Iolanda Vincelli, Salvatore Palmieri, Paola Tacchetti, Fortunato Morabito, Sara Bringhen, Giovanni Tripepi, Maria Teresa Petrucci, Serena Rocchi, Bruno Garibaldi, Vincenzo Pavone, Francesco Di Raimondo, Giuliana Farina, Nicola Cascavilla, Monica Galli, Antonino Neri, Stelvio Ballanti, Silvia Mangiacavalli, Maurizio Musso, Ilaria Rizzello, Ferdinando Frigeri, Massimo Offidani, Clotilde Cangialosi, Massimo Gentile, Antonella Bruzzese, Elena Zamagni, Anna Mele, Cirino Botta, Mario Boccadoro, Daniele Derudas, Marialucia Barone, Nicola Di Renzo, Concetta Conticello, Giovanni Reddiconto, Roberto Ria, Michele Cavo, Giuseppe Mele, Morabito, Fortunato, Zamagni, Elena, Conticello, Concetta, Pavone, Vincenzo, Palmieri, Salvatore, Bringhen, Sara, Galli, Monica, Mangiacavalli, Silvia, Derudas, Daniele, Rossi, Elena, Ria, Roberto, Catalano, Lucio, Tacchetti, Paola, Mele, Giuseppe, Vincelli, Iolanda Donatella, Martino, Enrica Antonia, Vigna, Ernesto, Botta, Cirino, Bruzzese, Antonella, Mele, Anna, Pantani, Lucia, Rocchi, Serena, Garibaldi, Bruno, Cascavilla, Nicola, Ballanti, Stelvio, Tripepi, Giovanni, Frigeri, Ferdinando, Falcone, Antonetta Pia, Cangialosi, Clotilde, Reddiconto, Giovanni, Farina, Giuliana, Barone, Marialucia, Rizzello, Ilaria, Musto, Pellegrino, De Stefano, Valerio, Musso, Maurizio, Petrucci, Maria Teresa, Offidani, Massimo, Neri, Antonino, Di Renzo, Nicola, Di Raimondo, Francesco, Boccadoro, Mario, Cavo, Michele, and Gentile, Massimo
- Subjects
Oncology ,medicine.medical_specialty ,Salvage therapy ,Antibodies, Monoclonal, Humanized ,Dexamethasone ,Settore MED/15 - Malattie Del Sangue ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Elotuzumab ,Lenalidomide ,Multiple myeloma ,Retrospective Studies ,Salvage Therapy ,carfilzomib ,business.industry ,Hazard ratio ,Hematology ,General Medicine ,medicine.disease ,Carfilzomib ,elotuzumab ,multiple myeloma ,chemistry ,Cohort ,business ,Oligopeptides ,medicine.drug - Abstract
The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categories, detected in roughly one-third of cases, were equally distributed between the two therapy arms. The probability of CR+VGPR response was significantly higher in KRd (n = 314, 53.9%) than in EloRd patients (n = 111, 37.0%). Likewise, the cumulative incidence function of CR+VGPR, taking into account the competitive risk of death, was significantly higher in KRd arm patients than those in the EloRd arm (p = .003). Moreover, KRd treatment significantly reduced the progression or death risk by 46% in an adjusted multivariate analysis (HR: 0.54, 95% CI 0.42-0.69, p .0001). Finally, in an adjusted illness-progression/death model, the effect of KRd versus EloRd was of higher magnitude among those who achieved CR+VGPR (-39% hazard ratio reduction, p = .02) than among those who achieved VGPR (-29% hazard ratio reduction, p = .007). With limitations characteristic to any retrospective analysis, this current clinical practice study's overall results demonstrated potential benefits of KRd therapy compared with EloRd. This observation may help the daily clinical practice.
- Published
- 2021
11. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
- Author
-
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Donatella Vincelli I, Antonia Martino E, Vigna E, Botta C, Bruzzese A, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Pia Falcone A, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Musto P, De Stefano V, Musso M, Teresa Petrucci M, Offidani M, Neri A, Di Renzo N, Di Raimondo F, Boccadoro M, Cavo M, and Gentile M
- Subjects
- Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dexamethasone, Humans, Lenalidomide, Oligopeptides, Retrospective Studies, Salvage Therapy, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy
- Abstract
The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categories, detected in roughly one-third of cases, were equally distributed between the two therapy arms. The probability of CR+VGPR response was significantly higher in KRd (n = 314, 53.9%) than in EloRd patients (n = 111, 37.0%). Likewise, the cumulative incidence function of CR+VGPR, taking into account the competitive risk of death, was significantly higher in KRd arm patients than those in the EloRd arm (p = .003). Moreover, KRd treatment significantly reduced the progression or death risk by 46% in an adjusted multivariate analysis (HR: 0.54, 95% CI 0.42-0.69, p < .0001). Finally, in an adjusted illness-progression/death model, the effect of KRd versus EloRd was of higher magnitude among those who achieved CR+VGPR (-39% hazard ratio reduction, p = .02) than among those who achieved < VGPR (-29% hazard ratio reduction, p = .007). With limitations characteristic to any retrospective analysis, this current clinical practice study's overall results demonstrated potential benefits of KRd therapy compared with EloRd. This observation may help the daily clinical practice., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.